{'fraction_non_alphanumeric': 0.03651354534746761, 'fraction_numerical': 0.04004711425206125, 'mean_word_length': 4.448717948717949, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Bone Resorption in Vitro and in Vivo in PGE-Treated Mice 1

Summary The bone-resorbing activity of prostaglandin was assessed in neonatal mouse calvaria maintained in culture as well as in the bones of adult mice in vivo. In an in vitro 45Ca-release bioassay, PGE2, the most active compound, produced a maximal stimulation of radiocalcium bone depletion of 89% versus 38% for PGF2α and 12% for PGA1. Daily intraperitoneal injection of 10 μg of 16,16-dimethyl-PGE2-methyl ester, a long-acting synthetic analog of PGE2, in several groups of C57/B1/6J mice produced a mean 33% loss of trabecular bone and a 140% increase in the area of bone lined by osteoclasts. Moreover, treatment of 4-month-old mice with di-M-PGE2 for 4 days caused a mean 15% depletion of bone calcium. There were no significant changes in blood calcium with the protocol employed.